同源康医药-B获浙江省药品监督管理局颁发《药品生产许可证》

Core Viewpoint - The company has received a Drug Manufacturing License from the Zhejiang Provincial Drug Administration, which is expected to positively impact its capacity expansion and market development in the long term [1] Group 1: License Acquisition - The company has been granted a Drug Manufacturing License, which lays the foundation for future commercial production [1] - This license is anticipated to enable the company to provide better treatment options for patients, addressing urgent medical needs in cancer treatment [1] Group 2: Market Impact - The acquisition of the license is expected to have a long-term positive effect on the company's ability to expand its production capacity and market reach [1]